Fujitsu / DS Pharma / Sumitomo Dainippon Pharma Group / Sumitomo Chemical / PARI Pharma GmbH / Annual Report 2014 Sumitomo Dainippon Pharma Co. Ltd. / SanBio Inc. / Annual Report 2014 30 Development Sumitomo Dainippon Pharma / Edison Pharmaceuticals Inc. / Boston Biomedical Inc. / Japan BCG Laboratory / Intercept Pharmaceuticals Inc. / New TB Vaccine Create Vaccine Company Ltd. / Sumitomo Dainippon Pharma Co. Ltd. / Oncology Sumitomo Dainippon Pharma / U.S. Sanbio Inc. / Medicine & Cell Therapy Sumitomo Dainippon Pharma / Research & Development Sumitomo Dainippon Pharma / Sumitomo Pharmaceuticals / Healios K.K. / Medicine & Cell Therapy Toru Kimura / Sumitomo Dainippon Pharma Co. / Therapy Sumitomo Dainippon Pharma / /
Continent
North America / /
Country
Japan / Canada / United Kingdom / China / United States / /
Event
FDA Phase / Patent Filing / Business Partnership / M&A / /
Facility
Kyoto University / Keio University / National Hospital Organization Osaka National Hospital / Osaka University / University The Graduate School / Kyoto University Kyoto University / Main Research Partners Partner Details The Laboratory / National Institute of Biomedical Innovation / RIKEN Advanced Institute / Port Island / /
IndustryTerm
individual products / vector technology / redox systems / pharmaceuticals / analytical technology / treatment for mitochondrial diseases / product life cycle management / chemical entity / file patent applications / manufacturing / regenerative medicine-related products / pharmacokinetic technology / clinical applications / scientific technologies / biotechnology / treatment of eye diseases / basic technology / pharmaceutical manufacturer / manufacturing methods / energy generation / treatment of ADHD symptoms / active pharmaceutical ingredients / pharmaceutical / diagnostic systems / patents/patent applications / investigational and new drug applications / omics technologies / synthetic chemistry technology / pharmaceutical research department / rhPIV2 vector technology / candidate pharmaceutical compounds / therapy for stroke / /
MedicalCondition
strokes / Hematologic cancer WT4869 / Development Disease / Dementia / retinitis pigmentosa / active / infectious form / oxidative stress-induced neuropsychiatric disorders / Development location Gastric cancer / heterogeneous cancer / SB623 Stroke / mitochondrial diseases / rare intractable diseases / Wilms’ tumor / ADHD / cancer / schizophrenia / Parkinsonism / bipolar depression / Hepatocellular carcinoma / mitochondrial disease / carcinogenesis / I depression / Chronic / stroke / cognitive impairment / diabetes / hematologic cancers / I Gastrointestinal cancer / depression / eye diseases / disorders / Gastric cancer / Urothelial carcinoma / obstructive pulmonary disease / TB / dasotraline Attention-deficit hyperactivity disorder / Colorectal cancer / certain diseases / development comprising disease / metastasis / mal tumor / solid tumors / developmental disorders / hepatic dysfunction / Canada Solid tumors / mental disease / age-related macular degeneration / Myelodysplastic syndromes Japan Solid tumors Japan Solid tumors / Renal cell carcinoma / intractable diseases / constipation / III Submitted Small cell lung cancer China Colorectal cancer / Primary biliary cirrhosis / Attention-deficit hyperactivity disorder / Cholangiocarcinoma / Gastro-esophageal junction adenocarcinoma / spinal cord injury / hepatic fibrosis / Alzheimer’s disease / disease / glycopyrrolate bromide Chronic / Leigh syndrome / WT2725 Solid tumors / pain / BBI503 Solid tumors BBI608 / rare intractable disease / Japan Solid tumors / eye disease / /
MedicalTreatment
Adjunctive therapy / Cell Therapy / /
NaturalFeature
Port Island / /
Organization
Osaka University / Dainippon Pharma Cancer Institute Independent / Patent Committee / Cooperation Center / Kyoto University / Kobe Regenerative & Cellular Medicine Center / Drug Development Division in Japan / National Institute of Biomedical Innovation / Laboratory for Malignancy Control Research / RIKEN Advanced Institute for Computational Science / Independent Administrative Agency / Graduate School / Keio University / Center for iPS Cell Research / Pharmaceuticals and Medical Devices Agency / Center for iPS Cell Research and Application Platform / National Hospital Organization Osaka National Hospital / /
Special Feature Innovation New Opportunities in Regenerative Medicine & Cell Therapy In its third Mid-term Business Plan (the 3rd MTBP), Sumitomo Dainippon Pharma points to